BioProcess International Spotlights Modicus Prime's AI Cloud Technology

In an era where significant events define the times, 2020 stood out for many reasons. While the year was meant to celebrate global unity through the 2020 Tokyo Olympics, it instead became synonymous with the COVID-19 pandemic. Amid lockdowns, social distancing, and supply shortages, the world of biomanufacturing emerged as a critical player. As pharmaceutical companies rushed to develop and distribute vaccines, they faced challenges, including a notable incident where nearly 400 million doses of vaccines were destroyed due to contamination fears. This highlighted systemic issues in drug-product quality, costing the industry billions annually. Taylor Chartier, CEO and founder of Modicus Prime, leveraged her expertise in AI to address these pervasive quality lapses, establishing the company during the pandemic with a vision to enhance pharmaceutical production using advanced AI solutions.

Modicus Prime recently secured $3.5 million in seed funding, led by Silverton Partners, to further develop its mpVision cloud software. This technology, designed for real-time quality assurance, is already implemented across several global pharmaceutical companies and CDMOs. Chartier’s team created mpVision to meet industry needs such as compliance, faster market entry, and reduced operating costs. The software integrates with various camera-equipped devices and uses AI for scalable, accurate quality control. By enabling real-time monitoring and defining specific metrics and alerts, mpVision helps ensure drug product purity and identity, thereby preventing contamination. This innovation has proven to be a differentiator for CDMOs, enhancing their manufacturing processes and providing significant time and cost savings, reinforcing Modicus Prime’s commitment to advancing biopharmaceutical quality through cutting-edge AI technology.

Read more about this Pharma 4.0 quality control technology, mpVision, published in BioProcess International.

About Modicus Prime

Modicus Prime’s computer vision software automates biologics image analysis and is designed to solve for the cost, legal, and waste liabilities from product quality failures across R&D and manufacturing.  A resident of Johnson & Johnson’s JLABS at the Texas Medical Center, Modicus Prime is venture-backed and has strategic partnerships with organizations including Takeda Pharmaceuticals, Oak Ridge National Laboratory (DOE), Dotmatics, eLabNext (Eppendorf), and PlugandPlay Health. Current implementation areas for the software include biologics, cell and gene therapies (including AAV manufacturing), and vaccines for pharmaceutical manufacturing, CMOs, CDMOs, and CROs.